abs327.txt	purpose		to	identify	clinical	parameters	that	are	prognostic	for	improved	overallsurvival	(os)	after	yttrium-90	radioembolization	(re)	in	patients	with	livermetastases	from	colorectal	cancer	(crc)	materials	and	methods		a	total	of	131	patients	who	underwent	re	for	livermetastases	from	crc		treated	at	2	academic	centers		were	reviewed		twenty-onebaseline	pretreatment	clinical	factors	were	analyzed	in	relation	to	os	by	thekaplan-meier	method	along	with	log-rank	tests	and	univariate	and	multivariate	coxregression	analyses	results		the	median	os	from	first	re	procedure	was	10	7	months	(95%	confidenceinterval	[ci]		9	4-12	7	months)		several	pretreatment	factors		including	lowercarcinoembryonic	antigen	(cea		≤20	ng/ml)		lower	aspartate	transaminase	(ast		≤40iu/l)		neutrophil-lymphocyte	ratio	(nlr)	<5		and	absence	of	extrahepatic	diseaseat	baseline	were	associated	with	significantly	improved	os	after	re		comparedwith	high	cea	(>20	ng/ml)		high	ast	(>40	iu/l)		nlr	≥5		and	extrahepaticmetastases	(p	values	of	<	001		<	001			0001		and		04		respectively)		onmultivariate	analysis		higher	cea		higher	ast		nlr	≥5		extrahepatic	disease		andlarger	volume	of	liver	metastases	remained	independently	associated	with	risk	ofdeath	(hazard	ratios	of	1	63		2	06		2	22		1	48		and	1	02		respectively)	conclusions		the	prognosis	of	patients	with	metastases	from	crc	is	impacted	by	acomplex	set	of	clinical	parameters		this	analysis	of	pretreatment	factorsidentified	lower	ast		lower	cea		lower	nlr		and	lower	tumor	burden	(intra-	orextrahepatic)	to	be	independently	associated	with	higher	survival	after	hepaticre		optimal	selection	of	patients	with	crc	liver	metastases	may	improve	survivalrates	after	administration	of	yttrium-90	
